Omnicell, Inc. (NASDAQ:OMCL) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Omnicell, Inc. (NASDAQ:OMCL) have been given an average rating of “Moderate Buy” by the eight research firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $58.50.

Several research analysts have weighed in on OMCL shares. Wall Street Zen cut Omnicell from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Piper Sandler reiterated an “overweight” rating and set a $49.00 target price (down from $63.00) on shares of Omnicell in a research note on Friday, February 6th. KeyCorp raised shares of Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price target on the stock in a report on Wednesday, January 7th. Zacks Research upgraded shares of Omnicell from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. Finally, Weiss Ratings downgraded shares of Omnicell from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, March 2nd.

Omnicell Price Performance

Omnicell stock opened at $32.35 on Tuesday. Omnicell has a 52 week low of $22.66 and a 52 week high of $55.00. The company’s 50 day moving average price is $40.28 and its two-hundred day moving average price is $38.61. The company has a quick ratio of 1.22, a current ratio of 1.43 and a debt-to-equity ratio of 0.14. The stock has a market cap of $1.47 billion, a P/E ratio of 808.95, a P/E/G ratio of 1.17 and a beta of 0.79.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, February 5th. The company reported $0.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.47 by ($0.07). The business had revenue of $313.98 million during the quarter, compared to the consensus estimate of $313.36 million. Omnicell had a net margin of 0.17% and a return on equity of 3.00%. The business’s revenue was up 2.3% on a year-over-year basis. During the same period in the prior year, the company earned $0.60 earnings per share. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. On average, equities analysts predict that Omnicell will post 1.09 earnings per share for the current year.

Insider Activity

In other news, EVP Corey J. Manley sold 7,405 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $34.69, for a total transaction of $256,879.45. Following the completion of the sale, the executive vice president owned 96,717 shares in the company, valued at $3,355,112.73. This trade represents a 7.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.52% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Omnicell

Several institutional investors and hedge funds have recently bought and sold shares of the company. Dimensional Fund Advisors LP raised its stake in shares of Omnicell by 9.1% in the third quarter. Dimensional Fund Advisors LP now owns 2,364,068 shares of the company’s stock valued at $71,985,000 after buying an additional 197,462 shares during the period. Wellington Management Group LLP grew its stake in shares of Omnicell by 156.4% during the 4th quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock worth $94,014,000 after acquiring an additional 1,265,818 shares during the period. Lazard Asset Management LLC grew its stake in shares of Omnicell by 3.8% during the 2nd quarter. Lazard Asset Management LLC now owns 1,708,345 shares of the company’s stock worth $50,225,000 after acquiring an additional 62,733 shares during the period. Geode Capital Management LLC increased its holdings in Omnicell by 2.6% in the 2nd quarter. Geode Capital Management LLC now owns 1,195,896 shares of the company’s stock worth $35,163,000 after acquiring an additional 30,678 shares during the last quarter. Finally, Millennium Management LLC purchased a new stake in Omnicell in the 3rd quarter worth about $25,625,000. 97.70% of the stock is owned by institutional investors.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.